c21
Small moleculeexperimental
Clinical trial activity
7 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jan 3, 2020 (NCT04388176)
Timeline
Indications
Mechanism of action
- Type-1 angiotensin II receptorACTIVATOR
AGTR1 activator
Chemistry & pharmacology
Loading structure…
SMILES
CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2ccnc2)cc1- Mol. weight
- 475.64 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL189568 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06588686 | Phase 2 | Oct 31, 2024 | Population Services International, Vicore Pharma AB |
| NCT05831644 | Phase 1 | Apr 25, 2023 | Vicore Pharma AB |
| NCT05277922 | Phase 1 | Apr 28, 2022 | Clinical Trial Consultants AB, Vicore Pharma AB |
| NCT04880642 | Phase 3 | Sep 16, 2021 | Vicore Pharma AB |
| NCT04533022 | Phase 2 | Sep 30, 2020 | Orphan Reach, Vicore Pharma AB |
| NCT04452435 | Phase 2 | Jul 21, 2020 | Orphan Reach, Vicore Pharma AB |
| NCT04388176 | Phase 2 | Jan 3, 2020 | Salford Royal Foundation NHS Trust, SGS Life Sciences, Vicore Pharma AB |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vicore Pharma AB | For profit | 7 | 7 | 3 | 2020 |
| Orphan Reach | For profit | 2 | 0 | 1 | 2020 |
| Clinical Trial Consultants AB | For profit | 1 | 0 | 1 | 2022 |
| Population Services International | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Salford Royal Foundation NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2020 |
| SGS Life Sciences | For profit | 1 | 0 | 1 | 2020 |
6 organizations
Page 1 / 1